Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million

Reuters

昨天

Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million

HeartCare published an annual results announcement for the year ended Dec. 31, 2025.
Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.
Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.
Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.
Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2622593988"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622593988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622593988?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622593988","market":"nz","top_or_hot":-1,"title":"Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          HeartCare published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.\n        </li>\n<li>\n          Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.\n        </li>\n<li>\n          Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.\n        </li>\n<li>\n          Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 18:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          HeartCare published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.\n        </li>\n<li>\n          Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.\n        </li>\n<li>\n          Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.\n        </li>\n<li>\n          Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9K5rFt:1","article_id":"2622593988","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622593988","pubTimestamp":1774521700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HeartCare published an annual results announcement for the year ended Dec. 31, 2025.Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06609":"心玮医疗-B","BK1587":"次新股","BK1100":"医疗保健设备"},"translate_title":"上海心康医疗科技2025财年税前利润跃升至人民币8600万元；收入增长46.9%至人民币4.08亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06609":0.9},"content_text":"Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n    \n\n\n          HeartCare published an annual results announcement for the year ended Dec. 31, 2025.\n        \n\n          Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.\n        \n\n          Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.\n        \n\n          Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.\n        \n\n          Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}